Federated Hermes, Inc. Immatics N.V. Transaction History

Federated Hermes, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$8.05 - $11.58 $3.49 Million - $5.01 Million	-433,000 Reduced 20.56%	1,673,000 $14.6 Million
Q2 2022 Aug 15, 2022	SELL	$6.0 - $9.37 $2.1 Million - $3.28 Million	-350,000 Reduced 14.25%	2,106,000 $18.3 Million
Q3 2021 Nov 15, 2021	BUY	$11.58 - $15.46 $8.11 Million - $10.8 Million	700,000 Added 39.86%	2,456,000 $31.9 Million
Q3 2020 Nov 12, 2020	BUY	$8.73 - $15.15 $15.3 Million - $26.6 Million	1,756,000 New	1,756,000 $18.6 Million

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $623M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.